LIFE
aTyr Pharma, Inc.
1.18
USD
This page is just a preview of the data found in TrendSpider’s full version
aTyr Pharma, Inc. stock is down -5.6% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 November’s closed higher than October.
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trials for treatment of other interstitial lung diseases (ILDs) The company was incorporated in 2005 and is headquartered in San Diego, California.
